NCT05334823招募中2 期
A Phase II Clinical Study of Anti-CD19 CAR-T Therapy (pCAR-19B) in the Treatment of CD19-positive Relapsed/Refractory B-ALL
Chongqing Precision Biotech Co., Ltd17 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2022年1月26日最近更新:
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 100
- 试验地点
- 17
- 主要终点
- Objective response rate after pCAR-19B infusion [Effectiveness]
研究概览
简要总结
This is a phase II clinical study to evaluate the safety and efficacy of pCAR-19 B cell autologous infusion preparation in the treatment of CD19-positive relapsed/refractory B-cell acute lymphoblastic leukemia.
详细描述
This is a multiple-center, single-arm, open-label study. After meeting the eligibility criteria and enrolling on the trial, patients will undergo leukapheresis for collection of autologous lymphocytes. Once cells have been manufactured, patients will then proceed to lymphodepleting chemotherapy with cyclophosphamide 20mg/kg and fludarabine 25mg/m^2 for 3 consecutive days followed by the infusion of CD19 CAR T-cells at a target dose of 0.6-2 x10^6 cells/kg.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 3 Years 至 21 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The patient himself or his guardian agrees to participate in this clinical trial and signs the Informed Consent Form (ICF), indicating that he understands the purpose and procedures of this clinical trial and is willing to participate in the research;
- •Diagnosed with B-ALL，and meet one of the following conditions:
- •Refractory B-ALL: early-stage refractory patients who failed to achieve complete remission after 2 courses of standard induction chemotherapy;
- •Relapsed B-ALL: patients with early relapse (<12 months) after complete remission;or late relapse (≥12 months) after complete remission, and relapsed patients who have not achieved complete remission after standard treatment or have poor response to early treatment; experience Patients with 2 or more bone marrow recurrences; patients with recurrence after allogeneic hematopoietic stem cell transplantation;
- •For Ph+ALL patients, patients who have not achieved complete remission after receiving at least two Tyrosine kinase inhibitors (TKI) treatments or have relapsed after complete remission (except those who cannot tolerate TKI treatment or have contraindications to TKI treatment or have T315i mutation resistance to TKI drugs);
- •The malignant cells in the bone marrow were confirmed to express CD19 by flow cytometry;
- •Bone marrow morphology at the time of screening indicated that blasts≥ 5%;
- •Eastern Cooperative Oncology Group (ECOG) 0-1 points ;
- •Expected survival is ≥ 12 weeks;
- •The function of important organs is basically normal:
- •Cardiac function: echocardiography showed cardiac ejection fraction ≥50%, and no obvious abnormality was found on electrocardiogram;
- •Renal function: serum creatinine≤2.0×ULN;
- •Liver function: Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) ≤5.0×ULN;
- •Total bilirubin≤2.0×ULN (for Gilbert syndrome, total bilirubin≤3.0×ULN);
- •Blood oxygen saturation≥92% in non-oxygen state.
- •No serious mental disorder;
- •Have apheresis or venous blood collection standards, and have no other contraindications for cell collection;
- •Subjects of childbearing age agree to use reliable and effective contraceptive methods for contraception (excluding rhythm contraception) from signing the informed consent to receiving pCAR-19B cell infusion within 1 year.
排除标准
- •Relapse of isolated extramedullary disease;
- •Active central nervous system leukemia at screening, defined as Central Nervous System (CNS)-grade 2 and 3 according to National Comprehensive Cancer Network (NCCN) guidelines (note: those with central nervous system involvement but improved after treatment can be included);
- •Those who have received CAR-T therapy or other gene-modified cell therapy before screening;
- •Received anti-CD19 drug treatment before screening;
- •Received the following anti-tumor treatments before screening: Received chemotherapy, targeted therapy and other drug treatments within 14 days or at least 5 half-lives (whichever is shorter); Received radiotherapy within 14 days;
- •HBsAg or HBcAb positive and hepatitis B virus (HBV) DNA is greater than the normal range; hepatitis C virus (HCV) antibody is positive and HCV RNA greater than the normal range; HIV antibody positive; syphilis positive; Cytomegalovirus (CMV) DNA positive;
- •Have any of the following heart conditions:
- •New York Heart Association (NYHA) stage III or IV congestive heart failure;
- •Myocardial infarction or coronary artery bypass grafting within 6 months prior to enrollment (CABG);
- •Clinically significant ventricular arrhythmia, or history of syncope of unknown origin (by vasovagal except those caused by menstruation or dehydration);
- •History of severe non-ischemic cardiomyopathy;
- •Active infection or uncontrollable infection requiring systemic treatment within 1 week before screening;
- •The presence of grade 2-4 acute graft-versus-host disease (GVHD) or moderate to severe chronic GVHD within 4 weeks before screening;
- •Cerebrovascular accident or epileptic seizure within 6 months before screening;
- •Active autoimmune diseases；
- •Patients with malignant tumors other than acute lymphoblastic leukemia within 5 years before screening, except for fully treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, local prostate cancer after radical resection, and duct in situ after radical resection cancer;
- •Received live attenuated vaccine within 4 weeks before screening;
- •Participated in other interventional clinical studies before screening, including: the last use of unmarketed new drugs is less than 3 months from the time of cell reinfusion, or the last use of marketed drugs is less than 5 half-lives from the time of cell reinfusion;
- •Women who are pregnant or breastfeeding, and male or female subjects who plan to have children within 1 year after receiving pCAR-19B cell reinfusion;
- •Other investigators deem it inappropriate to participate in the study.
研究组 & 干预措施
pCAR-19B cells
Experimental
Infusion of pCAR-19B cells by dose of 0.6-2 x10^6 cells/kg
干预措施: pCAR-19B cells (Biological)
结局指标
主要结局
Objective response rate after pCAR-19B infusion [Effectiveness]
时间窗: 3 months
Objective response rate includes CR, CRi.
次要结局
- Minimal residual disease（MRD）(3 months)
- Immunogenicity of pCAR-19B cells(3 months)
- Relapse free survival after pCAR-19B infusion [Effectiveness](2 years)
- The incidence of Treatment Emergent Adverse Events (TEAE) of pCAR-19B infusion(2 years)
- Overall survival after pCAR-19B infusion [Effectiveness](2 years)
- Duration of response after pCAR-19B infusion [Effectiveness](2 years)
- Event free survival after pCAR-19B infusion [Effectiveness](2 years)
- the incidence of adverse events related to treatment of pCAR-19B infusion(2 years)
- Pharmacokinetic data parameters of Tmax(3 months)
- Pharmacokinetic data parameters of AUC0-90d(3 months)
- Pharmacodynamics data parameters of the degree of clearance(3 months)
- Best overall response after pCAR-19B infusion [Effectiveness](2 years)
- the incidence of adverse event of special interest (AESI) of pCAR-19B infusion(2 years)
- the incidence of RCL of pCAR-19B infusion(2 years)
- Pharmacokinetic data parameters of Cmax(3 months)
- Pharmacodynamics data parameters of CAR-T-related serum cytokines(3 months)
研究者
研究点 (17)
Loading locations...
相似试验
已完成
1 期
Phase I Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and AdolescentsRelapsed Pediatric ALLRefractory Acute Lymphoblastic LeukemiaAcute Lymphoblastic LeukemiaNCT04888468Chongqing Precision Biotech Co., Ltd9
Unknown
1 期
Phase I Study of pCAR-19B in the Treatment of Adult CD19-positive Relapsed/Refractory B-ALLAcute Lymphoblastic Leukemia, in RelapseRefractory Acute Lymphoblastic LeukemiaNCT04888442Chongqing Precision Biotech Co., Ltd18
进行中（未招募）
1 期
CD19-Car T Cell Therapy for the Treatment of Older Adults With Acute Lymphoblastic Leukemia in First RemissionB Acute Lymphoblastic LeukemiaNCT05707273City of Hope Medical Center18
招募中
1 期
Clinical Trial of Autologous CD19 CAR-T Cells (CNCT19) Therapy for Advanced Hepatocellular CarcinomaAdvanced Hepatocellular CarcinomaNCT06676982Zhejiang University12
Unknown
1 期
Anti-CD19 CAR-T Therapy Bridging to HSCT for CD19+ B-Cell MalignanciesB Cell LymphomaAcute Lymphoblastic LeukemiaNCT03366350Wuhan Sian Medical Technology Co., Ltd50